Skip to main content

MDxHealth Licenses Prognostic Prostate Cancer Biomarker From Philips

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a worldwide licensing agreement with Philips for the rights to manufacture and market Philips' recently validated phosphodiesterase-4D7 prostate cancer biomarker as a prognostic test.

The financial terms of the agreement have not been disclosed.

The agreement will enable MDxHealth to prepare the launch of its tissue-based InformMDx test for prostate cancer as the test will utilize the PDE4D7 biomarker to stratify patients according to their risk of disease progression and the development of secondary tumors. The company believes that InformMDx will provide actionable information to help clinicians guide post-biopsy treatment decisions at the time of diagnosis, as well as treatment decisions following prostatectomy.

PDE4D7 was recently validated in a 503-patient study published in European Urology Focus, which followed patients for 10 to 15 years to confirm the prognostic and incremental value of PDE4D7 compared to the established clinical risk metric, the company added.

"This is an exciting deal which moves us a step closer towards launching InformMDx, our fourth commercial test which we believe will be valuable in providing physicians with critical information required to make informed therapeutic decisions for men recently diagnosed with prostate cancer," MDxHealth CEO Jan Groen said in a statement. "In line with our growth strategy, MDxHealth will continue to expand the range and reach of our diagnostic offering as the demand for actionable and cost-effective diagnosis and patient-monitoring grows across healthcare systems globally."